---
title: Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor
  carfilzomib as therapy for ibrutinib-resistant CLL
date: '2025-01-25'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39863584/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20250126170510&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Chronic lymphocytic leukemia is a malignant lymphoproliferative disorder
  for which primary or acquired drug resistance represents a major challenge. To investigate
  the underlying molecular mechanisms, we generate a mouse model of ibrutinib resistance,
  in which, after initial treatment response, relapse under therapy occurrs with an
  aggressive outgrowth of malignant cells, resembling observations in patients. A
  comparative analysis of exome, transcriptome and proteome of sorted leukemic ...
disable_comments: true
---
Chronic lymphocytic leukemia is a malignant lymphoproliferative disorder for which primary or acquired drug resistance represents a major challenge. To investigate the underlying molecular mechanisms, we generate a mouse model of ibrutinib resistance, in which, after initial treatment response, relapse under therapy occurrs with an aggressive outgrowth of malignant cells, resembling observations in patients. A comparative analysis of exome, transcriptome and proteome of sorted leukemic ...